University of Maryland School of Medicine Dean Mark T. Gladwin, MD, announced today that the school will receive a $29 million research award over four years from the National Institutes of Health to lead a multicenter trial that aims to improve health outcomes in people who inject opioid drugs and are hospitalized with infectious complications of their drug use.